Published in J Natl Cancer Inst on December 09, 2008
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev (2013) 2.07
Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res (2009) 2.03
Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res (2009) 1.82
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst (2013) 1.81
Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. Clin Cancer Res (2013) 1.07
miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer (2013) 1.05
NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet (2015) 1.02
Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol (2011) 1.01
Epigenomic regulation of oncogenesis by chromatin remodeling. Oncogene (2016) 0.97
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol (2013) 0.91
Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol (2009) 0.88
Targeting Transcription Factors in Cancer. Trends Cancer (2015) 0.86
Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front Genet (2013) 0.82
Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res (2013) 0.81
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev (2015) 0.79
Insights on neoplastic stem cells from gel-based proteomics of childhood germ cell tumors. Pediatr Blood Cancer (2011) 0.78
The roles of SNF2/SWI2 nucleosome remodeling enzymes in blood cell differentiation and leukemia. Biomed Res Int (2015) 0.75
Deletion of Arid1a in Reproductive Tract Mesenchymal Cells Reduces Fertility in Female Mice. Biol Reprod (2016) 0.75
BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines. Clin Transl Oncol (2017) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
A global test for groups of genes: testing association with a clinical outcome. Bioinformatics (2004) 10.82
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
Sequence-specific positioning of nucleosomes over the steroid-inducible MMTV promoter. EMBO J (1987) 4.60
The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer (2004) 4.59
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors. Science (1992) 4.06
Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature (1998) 3.28
Recent advances in understanding chromatin remodeling by Swi/Snf complexes. Curr Opin Genet Dev (2003) 3.16
Transcription factor access is mediated by accurately positioned nucleosomes on the mouse mammary tumor virus promoter. Mol Cell Biol (1991) 2.56
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 2.48
Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ (2004) 1.95
The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids (2005) 1.83
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer (2006) 1.71
Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood (1998) 1.69
BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation. Mol Cell Biol (2003) 1.69
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol (2003) 1.67
Largest subunits of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors. J Biol Chem (2002) 1.61
Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia (2003) 1.46
Glucocorticoid receptor-glucocorticoid response element binding stimulates nucleosome disruption by the SWI/SNF complex. Mol Cell Biol (1997) 1.46
Reconstitution of glucocorticoid receptor-dependent transcription in vivo. Mol Cell Biol (2004) 1.45
Recruitment of the SWI-SNF chromatin remodeling complex as a mechanism of gene activation by the glucocorticoid receptor tau1 activation domain. Mol Cell Biol (2000) 1.39
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev (2006) 1.35
In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood (1997) 1.28
Nuclear receptors and chromatin remodeling machinery. Mol Cell Endocrinol (2007) 1.28
Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet (1991) 1.26
Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogen-activated protein (MAP) kinase. J Biol Chem (2004) 1.24
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood (1997) 1.18
Chromatin remodelling and transcription: be-WICHed by nuclear myosin 1. Curr Opin Cell Biol (2006) 1.13
Changes in attitude, changes in latitude: nuclear receptors remodeling chromatin to regulate transcription. Mol Endocrinol (2005) 1.13
Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood (2003) 1.11
Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood (2005) 1.07
Transcriptional regulation: SWItching circuitry. Curr Biol (1999) 1.06
Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. Blood (2006) 1.05
Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin. Mol Biol Cell (2001) 1.03
Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia. Leukemia (2004) 1.01
Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Hum Mol Genet (2007) 1.01
Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia (2000) 1.00
New and improved glucocorticoid receptor ligands. Expert Opin Investig Drugs (2005) 0.95
Splice site mutation in the glucocorticoid receptor gene causes resistance to glucocorticoid-induced apoptosis in a human acute leukemic cell line. Cancer Res (1995) 0.94
Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia. Haematologica (2005) 0.92
The human glucocorticoid receptor (GR) isoform {beta} differentially suppresses GR{alpha}-induced transactivation stimulated by synthetic glucocorticoids. J Clin Endocrinol Metab (2005) 0.92
Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia (2002) 0.91
Glucocorticoid receptor gene mutations in leukemic cells acquired in vitro and in vivo. Cancer Res (2000) 0.87
Cloning and expression of mutant glucocorticoid receptors from glucocorticoid-sensitive and -resistant human leukemic cells. Cancer Res (1993) 0.86
Transfection with steroid-responsive reporter constructs shows glucocorticoid rather than androgen responsiveness in cultured Sertoli cells. J Steroid Biochem Mol Biol (2006) 0.83
Glucocorticoid-receptor-gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines. Int J Cancer (1996) 0.82
Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a Pediatric Oncology Group Study. Cancer Res (1985) 0.82
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
"Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev (2008) 3.80
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med (2003) 3.57
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol (2011) 3.05
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
Direct ubiquitination of pattern recognition receptor FLS2 attenuates plant innate immunity. Science (2011) 2.93
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
Robust estimation of the false discovery rate. Bioinformatics (2006) 2.87
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77
Improving false discovery rate estimation. Bioinformatics (2004) 2.77
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta (2006) 2.62
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
Agrobacterium tumefaciens-mediated transformation of maize embryos using a standard binary vector system. Plant Physiol (2002) 2.43
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38